Exenatide: Uses, Mechanism, and Side Effects

Managing blood sugar in type 2 diabetes often means adding a medication alongside diet and exercise. Exenatide is one such option, used for years under the brand name Byetta.

Key takeaways

• Exenatide is a GLP-1 receptor agonist approved as an add-on to diet and exercise in adults with type 2 diabetes.
• It works by enhancing glucose-dependent insulin release, lowering glucagon, and slowing gastric emptying.
• More than 400 registered trials have studied exenatide, including head-to-head and combination studies.
• The most reported reactions involve blood glucose changes and gastrointestinal effects, especially nausea.
• The label does not carry a boxed warning.

What Exenatide Is

Exenatide belongs to a drug class called GLP-1 receptor agonists. It mimics the action of a natural gut hormone, glucagon-like peptide-1, that the body releases after eating. By activating the same receptor, exenatide boosts insulin secretion when blood sugar is high, reduces the release of glucagon (a hormone that raises blood sugar), and slows how quickly the stomach empties food. Its amino acid sequence partially overlaps with that of human GLP-1, which explains its similar effects (PubChem CID 45588096).

What Exenatide Is Approved For

Exenatide, marketed as Byetta, is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The label advises against combining it with other exenatide-containing products. No boxed warning is present on this label.

What the Evidence Shows

Exenatide has been studied in more than 400 registered clinical trials. These include a completed Phase 1 study examining the safety, tolerability, and pharmacokinetics of a once-weekly formulation in Japanese patients with type 2 diabetes. A completed Phase 4 trial also compared exenatide to biphasic insulin aspart for its effect on glucose variability in type 2 diabetes, and another Phase 4 study looked at combining exenatide with pramlintide to reduce after-meal blood sugar spikes.

Reported Side Effects

Reported cases in the FDA's adverse event reporting system are counts of submitted reports, not confirmed rates or proof of a cause-and-effect relationship. The most frequently reported effects relate to blood glucose changes, including increased blood glucose (15,472 reports) and decreased blood glucose (5,516). Weight decreased was also commonly reported (12,126), alongside a cluster of gastrointestinal effects: nausea (12,041), decreased appetite (5,643), vomiting (4,345), and diarrhoea (2,742). Dizziness was reported 2,674 times.